Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Company Limited

ADMA Biologics ADMA reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up 40% year over year) also missed the Zacks Consensus Estimate of $119 million.
Consequently, the stock has plunged post the earnings announcement on May 7.
Nonetheless, the company raised its annual revenue guidance for 2025 and 2026, concurrent with the quarterly results.
A single quarter's results should not determine any investment decision. Let us delve into ADMA’s fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice.
Asceniv’s Performance Fuels ADMA’s Growth
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.
Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Demand was record high in the first quarter. Consequently, ADMA expects Asceniv’s total revenue share to expand throughout 2025 and beyond.
ADMA anticipates accelerating new patient starts and further penetration in existing institutions, which would significantly expand its peak revenue potential driven by ramp up of long-term high-titer plasma supply contracts and continued benefit in real-world patient outcomes.
ADMA’s Progress With Another Candidate
ADMA expects to generate initial, proof-of-concept animal data before 2025-end for its lead R&D pipeline program, SG-001, a hyperimmune globulin targeting S. pneumonia.
ADMA believes that SG-001 has the potential to generate $300-500 million or more in high-margin annual revenues, with IP protection through at least 2037.
ADMA Raises Financial Targets
Along with providing first-quarter results, ADMA updated its outlook for 2025 and 2026. ADMA now expects to generate revenues of more than $500 million in 2025 and $625 million in 2026 (previous guidance: more than $490 million in 2025 and $605 million in 2026). Net income is projected to exceed $175 million in 20225 (same as before) and expected to increase to $245 million or more for 2026 (previous guidance: exceed $235 million in 2026).
ADMA’s Share Repurchase Program to Boost Earnings
ADMA recently authorized a common stock repurchase program of up to $500 million. The buyback will boost the bottom line.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have surged 37.7% year to date against the industry’s decline of 7.4%. The stock has outperformed the sector and the S&P 500 in this timeframe.
ADMA Outperforms Industry, Sector And S&P 500 Index
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 10.46x forward sales, higher than its mean of 3.32x and the industry’s 1.65x.
Image Source: Zacks Investment Research
Estimate Movement
Image Source: Zacks Investment Research
The EPS estimate for 2025 has moved north 1 cent to 71 cents but remained unchanged at 93 cents for 2026.
Invest in ADMA Stock
Large biotech companies are generally considered safe havens for investors interested in this sector. ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.
While the first-quarter performance was disappointing, the targeted market has significant growth potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.
Additionally, ADMA conducts all its manufacturing operations, end-market sales, and customer engagements exclusively within the United States. The tariffs implemented on foreign goods, services, and manufacturing are not expected to have an impact on ADMA and its supply chain or production operations.
The recent FDA approval for its innovative yield enhancement production process supports revenue growth and margin expansion opportunities. Hence, any dip can be used as a buying opportunity. For investors already owning the stock, staying invested would be a prudent move.
ADMA currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Grifols, S.A. (GRFS) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Currently, both Takeda Pharmaceutical Co. and Daiichi Sankyo Co., Ltd. - Sponsored ADR are holding a Zacks Rank of # 2 (Buy). Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. However, value investors will care about much more than just this.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
TAK currently has a forward P/E ratio of 9.51, while DSNKY has a forward P/E of 27.68. We also note that TAK has a PEG ratio of 0.27. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. DSNKY currently has a PEG ratio of 1.60.
Another notable valuation metric for TAK is its P/B ratio of 0.98. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, DSNKY has a P/B of 4.32.
Based on these metrics and many more, TAK holds a Value grade of A, while DSNKY has a Value grade of C.
Both TAK and DSNKY are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that TAK is the superior value option right now.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

Shares of AC Immune ACIU have lost 18.3% in the past month compared with the industry’s decline of 1.3%. The stock has underperformed the sector and the S&P 500 Index during this timeframe.
Earlier in the month, ACIU reported better-than-expected results for the fourth quarter. Nonetheless, shares of this Switzerland-based clinical-stage biopharmaceutical company continue to slide down.
Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.
ACIU Underperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
AC Immune’s Innovative Pipeline
AC Immune is utilizing its dual proprietary technology platforms, SupraAntigen and Morphomer, to develop drugs spanning multiple treatment modalities and targeting both established and emerging neurodegenerative pathologies. At present, ACIU is advancing therapeutic and diagnostic programs targeting five different types of misfolded pathological proteins related to Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders.
ACI-24.060 is AC Immune’s anti-Abeta active immunotherapy being evaluated in patients with AD and in subjects with Down Syndrome (DS). ACI24.060 is currently being tested at three different incremental doses in the phase Ib/II ABATE study (NCT05462106), and amyloid plaque reduction is being assessed using Abeta-PET imaging. The candidate has been granted Fast Track designation for the treatment of AD in the United States.
ACI-7104.056, an active immunotherapy targeting pathological a-syn, is currently being tested in the phase II study (VacSYn) in the EU and the UK.
ACI-35.030/JNJ-2056 is being evaluated in subjects with preclinical (i.e., pre-symptomatic) AD in the phase IIb study ReTain.
Apart from these, the pipeline includes P2620, a Tau-PET imaging agent discovered in collaboration with Life Molecular Imaging (late-stage clinical development in AD), ACI-15196 for PD (a phase I study will be initiated shortly), and others.
The market for neurodegenerative diseases like AD and PD is expected to grow significantly.
Collaborations Provide Funding to ACIU
ACIU has entered into strategic collaborations with pharma giants to advance its pipeline. In 2024, AC Immune entered into an exclusive option and license agreement with Takeda TAK for its active immunotherapies targeting Abeta, including ACI-24.060 for AD. AC Immune received an upfront payment of $100 million and is eligible to receive total potential payments of up to approximately $2.1 billion.
ACIU has collaborated with Janssen Pharmaceuticals, Inc., part of Johnson & Johnson JNJ, for ACI-35.030/JNJ-2056. In September 2024, the company received a milestone payment triggered by the rapid rate of prescreening in the potentially registrational phase IIb ReTain trial and the first patient was dosed in the second half of 2024. JNJ received Fast Track designation for JNJ-2056 from the FDA for AD in July 2024.
ACIU’s Cash Balance
ACIU owned cash resources of CHF 165.5 million as of Dec. 31, 2024. Management expects its cash balance to provide sufficient capital resources through the first quarter of 2027, assuming no other milestones are met.
ACIU Valuation and Estimates
Going by the price/sales ratio, ACIU’s shares are currently trading at a premium. The stock is currently trading at 6.15x forward sales, higher than its mean of 5.30x and the industry’s 1.70x.
Image Source: Zacks Investment Research
The loss per share estimate for 2025 has increased to 49 cents over the past 30 days.
Image Source: Zacks Investment Research
Stay Invested in ACIU
ACIU’s pipeline progress with key candidates is impressive. Potential positive data readouts on ACI-24.060 and ACI-7104.056 later in the year should boost investor sentiment. Collaboration with bigwigs like JNJ and Takeda provides funding to the company.
However, the targeted market of AD and PD is complex and obtaining approval for its candidates will be challenging. Any pipeline setback will adversely impact its growth prospects.
We advise prospective investors to wait for now before turning positive for ACIU. For investors already owning the stock, staying invested would be a prudent move.
ACIU currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
AC Immune (ACIU) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TKPHF.PK, TAK) announced on Monday that the European Medicines Agency or EMA has approved an additional 2 mL pre-filled pen option for Takhzyro or Lanadelumab. This approval is for the subcutaneous administration in adolescents, aged 12 years and above, and adult patients with recurrent hereditary Angioedema.
The company said that at present, Takhzyro is approved as 150 mg solution for injection in pre-filled syringe, 300 mg solution for injection in pre-filled syringe, and 300 mg solution for injection in vial. This latest approval for an additional subcutaneous administration option, i.e, the Takhzyro 300 mg solution for injection in pre-filled pen, containing 300 mg of Lanadelumab in 2 mL of solution, has been supported with clinical studies.
Hereditary Angioedema is a rare disorder causing painful and recurring attacks of oedema or swelling in different body parts like the abdomen, face, feet, genitals, hands and throat. These painful attacks can cause asphyxiation and can be life threatening.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Takeda Gets EMA Approval For Addl. Subcutaneous Administration Of Takhzyro In HAE Patients Aged 12+

(RTTNews) - Takeda (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA 10% Subcutaneous injection set in patients with agammaglobulinemia or hypogammaglobulinemia. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20.
"We are delighted that HYQVIA, approved in more than 40 countries worldwide, has now been approved in Japan," said Naoyoshi Hirota, Regional Head of Research & Development for Takeda's Plasma-Derived Therapies Business Unit in Japan.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Takeda Reports Approval Of HYQVIA Injection Set In Japan - Quick Facts

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that it will divest Teva-Takeda, its business venture in Japan, to JKI Co., Ltd. The divestment, which includes generics and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market.
As per the deal, all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
Teva expects the divestiture to be completed by April 1, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All employees of the business venture in Japan will remain employed, subject to the terms of the agreement.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Teva Pharma To Divest Teva-Takeda Business Venture In Japan To JKI

(RTTNews) - HUTCHMED (China) Limited (HCM) announced that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA (fruquintinib) 1mg/5mg capsules in Japan by its partner Takeda (TAK) for patients with previously treated metastatic colorectal cancer. This follows approval for the manufacturing and marketing of FRUZAQLA by the Japanese Ministry of Health, Labour and Welfare.
Takeda said in September 2024 that it received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg, a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

HUTCHMED To Receive Milestone Payment As Takeda Launches FRUZAQLA For Colorectal Cancer In Japan

(RTTNews) - Takeda (TKPHF.PK, TAK) reported first half net profit of 187.3 billion yen compared to 41.4 billion yen, last year. Core, non-IFRS, net profit was 489.1 billion yen, up 20.0%. Core, non-IFRS, revenue was 2.38 trillion yen, up 13.4%. Revenue growth was 5.0% at CER.
Fiscal 2024 Management Guidance has been upgraded, primarily due to milder than anticipated generic erosion of VYVANSE and strong business momentum. Core EPS is now projected to be down approximately 10%, revised from prior guidance of a decline of mid-10s%. Core revenue is now projected to be flat to slightly increasing, updated from prior outlook of flat to slightly declining. Core revenue, non-IFRS, is projected to be 4.48 trillion yen, updated from prior guidance of 4.35 trillion yen.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Takeda H1 Profit Rises; Upgrades 2024 Management Guidance

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Thursday, shares of Takeda Pharmaceutical Co Ltd (Symbol: TAK) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $13.78 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 62.2. A bullish investor could look at TAK's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of TAK shares:
Looking at the chart above, TAK's low point in its 52 week range is $12.575 per share, with $15.08 as the 52 week high point — that compares with a last trade of $13.80.
Find out what 9 other oversold stocks you need to know about »
Also see:
EVFM shares outstanding history
Funds Holding GRA
IIT Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Takeda Pharmaceutical Enters Oversold Territory (TAK)

Tempus AI, Inc TEM announced the expansion of its collaboration with Takeda Pharmaceutical Company Limited TAK. The tie-up expansion aims to enhance Takeda’s oncology research and development (R&D) efforts.
The latest announcement of an expanded partnership is expected to significantly boost Tempus’ biological modeling capabilities and solidify its foothold in the niche space.
Likely Trend of TEM Stock Following the News
Following the announcement on Sept. 26, 2024, shares of the company moved nearly 3.8% north to $53.84 till last trading.
Historically, the company has gained a high level of synergies from its partnerships and expertise in AI-enabled advancements in precision medicine. We expect market sentiment on the stock to continue to remain positive around this announcement, too.
Meanwhile, Tempus currently has a market capitalization of $8.31 billion. It has a current ratio of 3.70, higher than the industry’s 2.22. In the last reported quarter, TEM delivered a negative earnings surprise of 6.8%.
Rationale Behind the Expansion of Tempus’ Collaboration
Tempus and Takeda had earlier collaborated that leveraged Tempus’ de-identified multimodal datasets. The latest agreement is expected to expand upon that work.
Per Tempus, its multimodal real-world datasets and biological modeling capabilities will likely be combined by Takeda to advance its pipeline of cancer therapeutics. The pipeline includes antibody-drug conjugates and gamma delta T-cell therapies, among others. Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records and a suite of AI-enabled tools to accelerate critical insights for its drug development efforts.
It is worth mentioning that initial work has resulted in research that will be presented at an upcoming medical congress.
Additionally, the two companies have also commenced a multi-phase biological modeling project leveraging one of the largest repositories of patient-derived tumor organoids in the world.
Per Tempus’ management, the collaboration is expected to assist in efforts to accelerate Takeda’s growing oncology therapeutic pipeline, which may lead to the next generation of cancer treatments.
Industry Prospects in Favor of TEM
Per a report by Precedence Research, the global cancer therapeutics market is expected to be worth around $393.61 billion by 2032 from $164 billion in 2022, witnessing a CAGR of 9.2%. Factors like the rise in the prevalence of cancer cases and cancer research and an increase in the adoption of gene therapies and personalized medicine are likely to drive the market.
Given the market potential, the latest expanded collaboration is expected to provide a significant boost to Tempus’ business.
Tempus’ Recent Developments
This month, Tempus announced a multi-year collaboration with BioNTech SE. Under the collaboration, Tempus is expected to provide analytical support and computational biology expertise to BioNTech across its comprehensive R&D oncology pipeline.
Last month, Tempus reported its second-quarter 2024 results, wherein it recorded a robust year-over-year uptick in its overall revenues and data licensing revenues. During the quarter, the company expanded into the minimal residual disease market with the launch of both tumor-naïve and tumor-informed assays.
TEM’s Share Price Performance
Shares of the company have gained 61.5% in the past three months compared with the industry’s 17.4% rise and the S&P 500's 4.3% growth.
Image Source: Zacks Investment Research
Tempus’ Zacks Rank & Stocks to Consider
Currently, TEM carries a Zacks Rank #4 (Sell).
A couple of better-ranked stocks in the broader medical space are DaVita Inc. DVA and Baxter International Inc. BAX.
DaVita, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 17.5%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 17.7% compared with the industry’s 14.2% rise in the past three months.
Baxter, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10%. BAX’s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 17.7% compared with the industry’s 12.8% rise in the past three months.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Baxter International Inc. (BAX) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
Tempus AI, Inc. (TEM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	46.27 23.75
Price/Sales	1.48 3.01
P/B	0.87 2.20
P/FCF	10.43 18.30

Indicator	TTM Median
ROE	1.96 25.41
ROA	0.93 6.00
ROI	1.20 9.66
Net Worth	43.49 0.20
Quick Ratio	0.74 1.71
Current Ratio	1.26 2.83

Indicator	TTM Median
Net Profit Margin	3.24 10.25
Operating Margin	4.46 14.24
Gross Margin	66.10 68.57
Return on tangible equity	-5.74 53.53

Indicator	TTM Median
Revenue	7.73B 16.00M
Gross Profit	5.26B —
EBITDA	2.30B —

Takeda Pharmaceutical Company Limited

Indicators TAK

Valuation

Debts

Efficiency

Other ratios

Revenue